DAWN • NASDAQ
Day One Biopharmaceuticals, Inc.
$9.14
Stock Details
| Market Cap | 936,227,868 |
|---|---|
| Day Change | 1.84 (25.21%) |
| Volume | 10,413,820 |
| Avg Volume | 1,507,440 |
| Price Range | 5.635-16.76 |
Overview
| Country | US |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Financial Overview
| 52 Week High | 16.76 |
|---|---|
| 52 Week High Date | 2024-11-08 |
| 52 Week Low | 5.635 |
| 52 Week Low Date | 2025-08-06 |
| 10D Avg Trading Vol | 1.71584 |
| YTD Price Return Daily | -42.3836 |
| MTD Price Return Daily | -1.8817 |
Cash Flow
| TTM/Share | -2.29432 |
|---|---|
| Annual/Share | -0.9631 |
| Quarterly/Share | -0.6738 |
Price-to-Earnings
| Annual Ratio | 7.6559 |
|---|---|
| Quarterly Ratio | 9.6528 |
| TTM |
Revenue
| 3Y Growth | |
|---|---|
| 5Y Growth | |
| Annual/Share | 313.92 |
| TTM/Share | 1.8205 |
| 5Y Share Growth |
Earnings Per Share
| Annual | -1.0243 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 2.0316 |
|---|---|
| Annual Ratio | 2.5415 |
| TTM | 1.4297 |